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Onset of symptoms with salt loss syndrome in a patient with 
AFB08/3499+2T>C mutations. 
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E. B ignamin i  1
:Paediattic CF Center; Piemonte arm ~&lle d'Aosta, A.O. O.LR.M - XAnnG Torino, 
Italy, 2MoIeculat; Genetics Service, A.O. O.I.R.M - S.AnnG Torino, Italy, 
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A 3 year mad 6 months o ld g i r l  came to the P iedmont and Val le d 'Aosta  Reg iona l  
Centre for Cystic Fibrosis,  Turin, Italy, due to hypcehloremic and hyponatr iemic 
dehydrat ion wi th  fever. The ch i ld  was normal at the cystic f ibrosis neonatal  
screening. To d iaoaose cystic f ibrosis, a Gibson and Cooke's  test was used twice. 
Both tests were  signif icantly posit ive (145 meq/L  and 127 meq/L  o f  CI~;  DNA 
analysis on peripheral  b lood was performed:  us ing  OLA PCR SCR method only 
one mutat ion in the CFTR gene  was found (AF508). A second mutat ion was seen 
wi th  DHFLC method and direct sequenc ing (3499+2T>C).  
After  two years fo l low up the patient presents stable general  condit ions wi th  good 
development of  growth (weight/height:  25'h 50'hpercenti le). 
Pancreatic and hepat ic  involvements are also absent (normal fecal elastase, fecal  
fats absent, normal  enzymes mad echogr  aphy). 
The chest XRays  regular ly done for the annual control o f  patient showed no 
pathological  signs. 
The two monthly tbroat swab cultures, done unt i l  today resulted four t imes posit ive: 
Pseudomonas aeruginosa and £nterobacter  c loacae were isolated once and 
Staphi lcececus aureus twice. 
After  isolat ion of  Pseudomonas aeruginosa the patient was treated wi th  antibiotics: 
nebul ised TOBI  for twenty e ight  days and oral c iprof loxacin for fourteen days, 
wh ich  consequent ly eradicated the infection. 
Currently, the patient is treatment free. 
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SearChing for genes modifying the severity of pulmonary course of cystic fibrosis (CF) 
A S0bezy~a T0ma~ew~a 1, K C~cr~a ~, D Sands ~, R PiOr 0wsPd ~, M ~ffawi~P~ ~ad~eka ~, J ~al ~ 
Am~ The mare goal f ~l~s prqezt is to identify gene~ mochfiers, wl~eh molceula~ deleers of a~e related to the elitnc al 
heter ogene~y ofthe m~rMe~t a~oc~ of pulmonav] chsease in eys~ fibros*s pa~ents We have fueuaed on ~lae~ genes: AAT, 
M~L2 and/FN gamma products ofall o f them a~e ngagedin the mfl ~rr~rna~ ory respot*se ofCF p a~mnts du~ng bacterial 
lunginf~*mt*s 
Me~od~ The eha~acterioles f ex ~rr~ned p a~mnts group is described m Table 1 In eaae of ll p a~mnts the molezula~ 
• qaly~s of~la~ gems e anchdat e~ haa been done 
No of p a~mnts genoype Age range Mec~an age at 
%tal No of i*~ luded of the a~ chaDao~s ch aDaosis 
p a~mnts pr obant~ fan~lie~ C~/~R gem (yea~s) (yea~s) 
87 79 8 delFS08/ 1 month 15 + 24 
delFS08 125eaxs 
Cuxrent Mechan C0urse 0f chsease 
age range euxmnt No of 
(~ea~s) age (yea~s) severe moderate *r~ld dez e amd pa*mnts 
23~16 122+69 22 33 32 14 
Re~uR~ The ru*ult~ o f molezula~ nalysis haa be~n surr~na~ized n Table 2 
Course of chseaae 
~vere moderate *r~ld 
Age range at chaDaos*s ('~ears) 1month 10 1 month~ 1 month 12 
Me&an age at ch aDao~s (yea~s) 19 + 27 08 + 11 20 + 29 
R~qge of current age (~ea~s) 104 232 29 236 23 316 
Mech ~q current age (yea~s) 157±47 112±56 122±83 
Number of de£ea~ed patlel~ 12 (545%) 2 (61%) 0 (0%) 
AA2~ gene ZJM 1 (45%) 2 (61%) 1 (31%) 
SdM 0 (0%) 0 (0%) 0 (0%) 
M[M 21 (955%) 31 (939%) 31 (969%) 
19370/A OO 18 (818%) 28 (848%) 23 (718%) 
GA 4 (182%) 5 (152%) 8 (250%) 
AA 0 (0%) 0 (0%) 1 (03%) 
MBL2 gem MA 17(773%) 18(545%) 18(563%) 
0/A or 0]0 5 (227%) 13 (394%) 13 (406%) 
221G/C XFX 2 (91%) 1 (30%) 1 (31%) 
(y/X) X/Y 5 (227%) 13 (394%) 12 (375%) 
y/Y 15 (682%) 19 (576%) 19 (594%) 
lFNg(onma intron 1 A/A 11(500%) 15(455%) 16(500%) 
AfF 6 (973%) 12 (364%) 14 (438%) 
TIT 5 (227%) 6 (182%) 2 (63%) 
Ccmclu~io~ wesuapeet that the alle~e va~ian~ 0 o f the MBL2 gene and the T o f the lFN g(onma gene am related to rmld 
or severe form o f chseaae, r ~pez ~vely~ Tins 6tudy is being eon~ued~ 
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Alpha1 antib'ypsin (A1AT) deficiency among patients with cystic 
fibrosis 
B.J. Far ia 1, I .C .J. Far ia  1, A.B. A lvarez  2, J.D. R ibeiro  2, A .F. R ibei r  o 2, C .S. Ber tuzzo 1 
:Department of  Medical Genetics, State University of Carnp#u~s Medical School, 
Campinas, SP, Brazil; 2Department of  Pediatrics- Center for Investigation in 
Pediatrics, State University of Camp#u~s Medical School, Camp#los, SP, Brazil 
Cystic f ibrosis is a genet ic  disorder that dur ing  its course presents mainly 
pulmonary mad pancreatic manifestations. The correlat ion between genotype and 
phenotype is not clear in cystic f ibrosis. The  severity o f  d isease is not related to the 
CFTR genotype. A lpha  i antitt3,psin inhibits the pr oteases that re lease ilRlammatot3, 
reactions of  the plasma. Its most important i l lhibitory role is it act ion against 
leukceyt ic elastase. As  the def ic iency of  a lpha 1 ant i l rypsin has relevant pulmonary 
manifestations and is common in the area, we  bel ieve that it may be able to 
modulate pulmonary manifestat ions ha f ibrceyst ic patients. The  objective of  this 
study was to ascertain the distr ibut ion o f  A IAT  genotypes and severity o f  
pulmonary disease ha seventy patients wi th  cystic f ibrosis. A l l  the patients ha the 
study were cl in ical ly and r adio logical ly  evaluated in accordance wi th  their c l in ical  
evolution, pulmonary funct ion and oxygen saturation tests. N ine  patients wi th  cystic 
f ibrosis (12.8%) were heterozygotes for S or Z al le le or compound heterozygotes 
(SZ). No  s ignif icant dif ferences were found ha c l in ica l  severity o f  CF  between 
genotypes of  A1AT (c[ED]22 0.92, P= 0.63). No  s ignif icant dif ferences were  
found when the patients were separated by the presence or absence of  AFS08 
mutation. We conc luded that the common MS,  SS, MZ genotypes of  A IAT  
def ic iency that cause discreet to moderate protein def ic iency are not associated wi th  
lung d isease deter iorat ion ha patients wi th  cyst ic f ibrosis. 
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Cystic fibrosis mutations specba in Italy: a regional distribution 
L. V iv iml i  1, F. R iccard ino 9, Gmppo It al imlo F ibr  osi Cist ica 
e Istituto di Statistica Medica e B iometria, Univers#a di Milano, Italy, )Dipartimento 
di Genetica, Biologia e Biochimica, Univers#a di Torino, Italy 
Aims: Because the geographic  distr ibut ion o f  CFFR mutat ion frequencies is 
heterogeneous among I ta l ian regions, it is worth consider ing the distr ibut ion o f  the 
CF mutations at a micr  ogeogr aphic level. The a im of  the present study is to update 
the analysis o f  CF  mutat ion relat ive frequencies in the I ta l ian regions performed in 
1997 on the basis o f  the new data col lected. 
Methods: The data  were  co l lected in co l laborat ion  w i th  CF  Centres and 
Laborator ies and I ta l ian CF  Registry,  creat ing a database,  where  pat ients '  
genotypes, parents'  genotypes and the birth places of  the grandparents are recorded. 
The interrelations between I ta l ian regions mad mutat ion frequencies were  analysed 
by means of  a mult ivar iate approach. 
Results: At  present, more than 72CO CF chromosomes (i.e. about twice the number 
avai lable in 1997) der ived from more than 36(K) CF  patients, are recorded in the 
Registt3,. For about 5800 among those 72CO CF chromosomes,  the birth places of  
the two grandfathers and two grandmothers are known, a l lowing a detai led regional  
map of  the CF  mutat ional  spectrum in Italy. The h igh  number of  chromosomes 
tested a l lowed us (at variance wi th  the previous study) to analyse only mutations 
wi th  certain geographic  or ig in (both grandparents born in the same region). New 
data substantial ly conf i rmed the remits  reported in the previous study, ha part icular 
that there are many mutations (the so cal led private mutations) present in a s ingle  
reg ion  (such as T338I  in Sardinia). Furthermore a new mutat ion (2789+5G >A) 
wi th  a rather h igh  frequency (about 2%) was detected. 
Conclusions: Our results might  prove of  practical  use when des ign ing  strategies 
when p lant ing  populat ion screening for heterozygotes:  the carr ier status is not 
c l in ical ly or otherwise detectable by laboratory tests, i f  not by mutat ion analysis, 
and therefore a screening program should be p lanned on the basis o f  the mutat ion 
regional  prevalence. 
